Pharmacogenomics in Antithrombotic Therapy

Pharmacogenomics is increasingly important in personalizing antithrombotic therapy for patients at risk of thromboembolic events. By understanding how genetic variations influence drug metabolism and response, healthcare providers can optimize antiplatelet and anticoagulant treatments to maximize efficacy and minimize adverse effects. Variants in genes such as CYP2C19 and VKORC1 significantly affect patients' responses to medications like clopidogrel and warfarin. Implementing pharmacogenomic testing in clinical practice enables tailored treatment strategies, enhancing patient safety and outcomes. As pharmacogenomics continues to evolve, it will play a crucial role in personalized cardiovascular care.

    Related Conference of Pharmacogenomics in Antithrombotic Therapy

    November 19-20, 2025

    7th World Heart Congress

    Tokyo, Japan
    November 24-25, 2025

    36th Annual Cardiologists Conference

    Barcelona, Spain
    November 27-28, 2025

    32nd World Heartcare Summit

    Paris, France
    January 12-13, 2026

    12th International Heart Conference

    Dubai, UAE
    March 18-19, 2026

    15th World Heart Congress

    Paris, France
    March 23-24, 2026

    41st World Cardiology Conference

    London, UK
    April 08-29, 2026

    9th Annual Heart Rhythm Conference

    Vienna, Austria
    April 13-14, 2026

    9th World Heart and Brain Conference

    Tokyo, Japan
    May 14-15, 2026

    5th International Conference on Cardiology

    Rome, Italy
    May 21-22, 2026

    15th World Congress on Cardiology

    London, UK
    July 29-30, 2026

    30th World Cardiology Conference

    Paris, France

    Pharmacogenomics in Antithrombotic Therapy Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in